Here, we show that the oncogene src42A/SRC is a downstream target of Yki/YAP, and that SRC inhibitors are able to suppress YAP-induced tumor cell migration, providing SRC as an alternative target for Hippo-related cancer treatment. Here, SRC is linked to neoplasm.